C-RAD has received an order for five Catalyst™ systems, to be installed at different hospitals in Egypt. The order has a total value of approximately 4.3 MSEK.
The Catalyst™ systems will be delivered with a software configuration containing modules for Patient Setup and Positioning and Respiratory Gating, including Elekta MOSAIQ® system interfaces as well as the Response™ interface for beam control. The interfaces allow a seamless integration with the linear accelerator for patient synchronization and an automated patient setup and beam control to treat tumors that are moving due to respiratory motion.
The Catalyst™ and Sentinel™ systems offer the required technology to perform high-end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.
The delivery and installation of the systems is expected to occur in Q2 2017
“I am very pleased to announce this large order,” says Tim Thurn, CEO of C-RAD. “Last year we strengthened our sales and customer support organization. One focus was to further develop business cooperation with our strategic partners and key accounts. This large project is the first result of these activities.”
About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 43. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com
The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).
